medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2007, Number 3

<< Back Next >>

Arch Neurocien 2007; 12 (3)

Function and life equality with the use of olazapine and risperidone three year study in schizofreme patients

Adrianzén C, Dossenbach M, Leadbetter M

Language: Spanish
References: 41
Page: 139-147
PDF size: 112.56 Kb.


ABSTRACT

Objective: to evaluate the health results and the related costs of the antipsychotic medications available on the market, with emphasis on olanzapine, in outpatients with schizophrenia in naturalistic settings. Methods: 572 outpatients with schizophrenia (CIE-10 or DSM-IV) who began or changed to an oral antipsychotic medication were enrolled in blocks of 10 patients: 5 for olanzapine and 5 for other antipsychotics (AP) different to Olanzapine, according to the prescription at that time. The risk behaviors, the level of functioning, and the quality of life were analyzed with the EUROQOL-EQ-D5 scale and the Visual Analogue Scale. The use of health resources was also evaluated. The analysis compared the group that received olanzapine with the subgroups which received risperidone and typical antipsychotics (AT) in monotherapy. Results: similar percentages of suicide attempts, alcohol abuse/dependence and arrests were found in the three treatment groups. The rates of hostile and aggressive behavior were statistically lower with olanzapine vs TA (p = 0.0003). Olanzapine and risperidone proved superior in improving/maintaining a high level of social, work and housing status vs. TA. Olanzapine and risperidone showed better results in the 5 items of EQ-5D vs. TA but only olanzapine achieved a statistical difference vs. TA in self-care, daily activities and absence of anxiety/depression. A higher percentage of patients on olanzapine continued with the medication up to the three year endpoint (p ‹ 0.0001 olanzapine vs TA); discontinued treatment less due to problems of efficacy or intolerability (p = 0.0005 olanzapine vs TA and p ‹ 0.0001 olanzapine vs. TA respectively); had the lowest rates of hospitalization. Conclusions: olanzapine and risperidone were superior to the typical antipsychotics in improving the overall functioning of the patients which can be interpreted as greater and better social reintegration. The state of health and the quality of life improved with both atypicals but only olanzapine was statistically superior to the typicals. The patients on olanzapine remained in treatment for the longest period and abandoned treatment less due to problems of efficacy or intolerability. Less patients on olanzapine needed hospitalization and outpatient consultations versus typical medications which could mean savings in direct costs of the illness.


REFERENCES

  1. Cancro R, Meyerson A. Prevention of disability and stigma related to schizophrenia: a review. In: Schizophrenia/Second edition. Edited by Mario Maj & Norman Sartorius. WPA Series Evidence and experience in psychiatry John Wiley & Sons USA 2002.

  2. Lieberman J, Perkins D, Belger A. The early stages of Schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-97.

  3. McGlashan TH. Early detection and intervention in schizophrenia: Research. Schizophr Bull 1996;22:327-45.

  4. Blanchard JB, Nueser KT, Bellack AS. Anhedonia, positive and negative affect, and social functioning in schizophrenia. Schizophr Bull 1998; 24: 413-24.

  5. Andreasen NC. Affective flattening and the criteria for schizophrenia. Am J Psychiatry 1979; 136: 944-7.

  6. Binder J, Albus M, Hubmann W. Neuropsychological impairment and psychopathology in first-episode schizophrenic patients related to the early course of illness. Eur Arch Psychiatry Clin Neurosci 1997; 248: 70-7.

  7. Lieberman J, Perkins D, Belger A. The early stages of Schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-97.

  8. American Psychiatry Association. Practice guidelines for the treatment of psychiatric disorder. 2002, Washington.

  9. Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Europ Arch Psychiatry Clin Neuroscien 1999; 249: IV/90-IV/98.

  10. Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes in schizophrenia. A European comparison of olanzapine and haloperidol. Europ Neuropsychopharmacol 1999; 9 (Suppl 5): 289.

  11. Hamilton SH, Revicki DA, Genduso LA, Beasley ChM. Olanzapine versus placebo and haloperidol quality of life and efficacy results of the North American double-blind trail. Neuropsychopharmacol 1998;18:41-9.

  12. Martin C. Impact of olanzapine on quality of life in schizophrenia. Europ Psychiatry 1996; 11(Suppl 4) 252s.

  13. Grainger D, Edgell ET, Andersen J, Wang J. Resource use and quality of life of olanzapine compared with risperidone: results from an internacional randomized clinical trial. Europ Neuropsychopharmacol 1998; 8 (Suppl 2) S225-S6.

  14. Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophren Res 2003; 61: 303-14.

  15. Kinon B, Noordsy DL, Liu-Seifert H. Randomized, double-blind 6-month comparison of olanzapina and quetiapina in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006; 26: 453-61.

  16. Gorwood P. Meeting everyday challenges: Antipsychotic therapy in the real world. Europ Neuropsychopharmacol 2006; 16: S156-S62.

  17. Haley JC, Russo PA, Buesching DP. Schizophrenia care and assessment program, SCAP: a naturalistic approach to measuring schizophrenia outcomes. Europ Neurospychopharmacol 1998; 8 (Suppl 2):S217.

  18. Salveker D, Slade E, Mustafa K. Differential effects of atypical antipsychotic medication on earnings of schizophrenia patients: estimates from a prospective naturalistic study. Pharmacoeconom 2006; 24(2): 123-39.

  19. Montes JM, Ciudad A, Gascón J, Gómez JC, Grupo de estudio EFESO. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Progress in Neuropsychopharmacol Biol Psych 2003; 27: 667-672.

  20. Ritsner MS, Gibel A. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. Progress in Neuro-Psychopharmacol Biol Psych 2006; In press

  21. Dossenbach M, Erol A. el Mahfoud K, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psych 2004; 65 (3): 312-21.

  22. Assuncao S, Gargoloff P, Silva H, Aguilar J, Landa Fournais P, Adan P. Estado Funcional y calidad de vida en pacientes latinoamericanos con esquizofrenia tratados con un antipsicótico atípico o típico: Resultados de 12 meses del estudio Intercontinental Schizophrenia Outpatients Health Outcomes (IC-SOHO). Vertex Rev Arg de Psiquiatría 2005; 16: 332-41.

  23. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Eng J Med 2005; 353: 1209-23.

  24. Geddes J, Freemantle N, Harrison P, Bebbington P for the National Schizophrenia Guideline Development Group Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Schizophrenia Research 1999;35:51–68.

  25. Leucht S, Pitschel-Walz, GD, Kissling AG. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophren Res 1999;35:51-68.

  26. Davies JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psych 2003; 60: 553-64.

  27. Tempier R, Pawliuk N. Atypical versus conventional antipsychotic medication: Impact on subjective quality of life of patients with schizophrenia or related disorders. Europ Psych 2000; Suppl 2: S411.

  28. Podea DM, The quality of life in schizophrenia atypical antipsychotics. Europ Neuropsychopharmacol 2003; Suppl 4: S297.

  29. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophren Res 2002: 57: 201-8.

  30. Corrigan PW, Reinkle RR, Landsberger SA, Charate A, Toombs GA. The effects of atypical antipsychotic medication on psychosocial outcomes. Schizophren Res 2003;63:97-101.

  31. Gregor KJ, Hamilton SH, Edgell ET Functional outcomes in schizophrenia: A European comparison of olanzapine and haloperidol. Europ Neuropsychopharmacol 1999;9 (Suppl 5):289.

  32. Zhang PL, Santos JM, Newcomer J, Pelfrey BA, Jonson MC, Erausquin GA. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizoph Res 2004; 71:137-144.

  33. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psych 2001; 148:1449-54.

  34. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International suicide prevention trial (InterSePT). Arch Gen Psych 2003; 60:82–91.

  35. Bitter I, Czobor P, Dossenbach M, Volavka J. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). Europ Psych 2005;20: Issues 5-6:403-8.

  36. Krakowski M, Czobor P, Citrome L, Bark N, Cooper T. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psych 2006; 63: 622-9.

  37. Almond S, O’Donnell O. Cost analysis of the treatment of schizophrenia in the UK. Pharmacoecono 1998; 13: 575-88.

  38. Almond S, O’Donnell O, McKendrich J. The cost-analysis compared with haloperidol and risperidone in the treatment of schizophrenia in the UK. Europ Neuropsychopharmacol 1999: 9 (Suppl 5): 289-90.

  39. Revicki DA. Pharmacoeconomic studies of atypical antipsychotics drugs for the treatment of schizophrenia. Schizophren Res 1999; 35: S101-S9.

  40. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second vs First-Generation antipsychotic drugs in schizophrenia cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psych 2006; 63:1079-87.

  41. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Haiqun L, Stroup TS, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163:2080-9.




2020     |     www.medigraphic.com